Insufficient scRNA-seq data for expression of AKR1B15 at single-cell level.
Insufficient scRNA-seq data for expression of AKR1B15 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 95% | 66.38 | 20 / 21 | 40% | 4.53 | 204 / 504 |
esophagus | 40% | 57.61 | 575 / 1445 | 62% | 7.84 | 113 / 183 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.02 | 1 / 1 |
muscle | 99% | 418.74 | 793 / 803 | 0% | 0 | 0 / 0 |
stomach | 65% | 132.96 | 234 / 359 | 14% | 0.48 | 41 / 286 |
breast | 47% | 61.20 | 216 / 459 | 28% | 9.14 | 313 / 1118 |
tonsil | 0% | 0 | 0 / 0 | 71% | 8.06 | 32 / 45 |
uterus | 1% | 3.15 | 2 / 170 | 58% | 6.78 | 265 / 459 |
liver | 13% | 11.23 | 29 / 226 | 44% | 5.07 | 180 / 406 |
skin | 47% | 40.75 | 847 / 1809 | 6% | 0.24 | 27 / 472 |
lung | 1% | 0.32 | 4 / 578 | 48% | 7.97 | 553 / 1155 |
intestine | 33% | 26.06 | 318 / 966 | 14% | 0.41 | 73 / 527 |
adrenal gland | 37% | 9.83 | 96 / 258 | 7% | 0.18 | 17 / 230 |
adipose | 44% | 22.87 | 527 / 1204 | 0% | 0 | 0 / 0 |
thymus | 31% | 8.50 | 204 / 653 | 11% | 0.43 | 67 / 605 |
blood vessel | 24% | 8.59 | 324 / 1335 | 0% | 0 | 0 / 0 |
ovary | 1% | 0.17 | 2 / 180 | 21% | 1.39 | 92 / 430 |
kidney | 13% | 4.65 | 12 / 89 | 8% | 1.10 | 76 / 901 |
prostate | 15% | 16.46 | 37 / 245 | 3% | 0.06 | 13 / 502 |
pancreas | 0% | 0.05 | 1 / 328 | 15% | 0.58 | 27 / 178 |
heart | 9% | 2.36 | 76 / 861 | 0% | 0 | 0 / 0 |
brain | 1% | 0.10 | 14 / 2642 | 7% | 0.15 | 49 / 705 |
peripheral blood | 2% | 0.69 | 22 / 929 | 0% | 0 | 0 / 0 |
spleen | 0% | 0.07 | 1 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006703 | Biological process | estrogen biosynthetic process |
GO_0042572 | Biological process | retinol metabolic process |
GO_0005829 | Cellular component | cytosol |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005739 | Cellular component | mitochondrion |
GO_0047045 | Molecular function | testosterone 17-beta-dehydrogenase (NADP+) activity |
GO_0004303 | Molecular function | estradiol 17-beta-dehydrogenase [NAD(P)+] activity |
GO_0047655 | Molecular function | allyl-alcohol dehydrogenase activity |
GO_0004032 | Molecular function | aldose reductase (NADPH) activity |
GO_0052650 | Molecular function | all-trans-retinol dehydrogenase (NADP+) activity |
GO_0047886 | Molecular function | farnesol dehydrogenase activity |
Gene name | AKR1B15 |
Protein name | Aldo-keto reductase family 1 member B15 (EC 1.1.1.-) (EC 1.1.1.300) (EC 1.1.1.54) (Estradiol 17-beta-dehydrogenase AKR1B15) (Farnesol dehydrogenase) (EC 1.1.1.216) (Testosterone 17beta-dehydrogenase) (EC 1.1.1.64) |
Synonyms | |
Description | FUNCTION: [Isoform 1]: Catalyzes the NADPH-dependent reduction of a variety of carbonyl substrates, like aromatic aldehydes, alkenals, ketones and alpha-dicarbonyl compounds . In addition, catalyzes the reduction of androgens and estrogens with high positional selectivity (shows 17-beta-hydroxysteroid dehydrogenase activity) as well as 3-keto-acyl-CoAs . Displays strong enzymatic activity toward all-trans-retinal and 9-cis-retinal . May play a physiological role in retinoid metabolism . .; FUNCTION: [Isoform 2]: No oxidoreductase activity observed with the tested substrates. . |
Accessions | ENST00000457545.7 [C9JRZ8-2] ENST00000652743.1 [C9JRZ8-1] C9JRZ8 ENST00000423958.2 [C9JRZ8-2] |